Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KRON Kronos Bio	$0.88 +1.5%	$0.80	$0.65 ▼ $1.60	$53.72M	1.64	367,094 shs	54,089 shs
PEPG PepGen	$1.24 -3.9%	$1.40	$0.88 ▼ $19.30	$42.21M	1.16	844,248 shs	136,951 shs
PHGE BiomX	$0.39 -47.6%	$0.48	$0.34 ▼ $3.58	$10.86M	1.41	332,206 shs	53,300 shs
PRLD Prelude Therapeutics	$0.81 -0.5%	$0.89	$0.61 ▼ $6.80	$46.24M	1.22	289,421 shs	90,162 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KRON Kronos Bio	0.00%	0.00%	-1.41%	0.00%	-38.89%
PEPG PepGen	-3.88%	+6.90%	-13.29%	+0.81%	-92.50%
PHGE BiomX	-8.08%	-11.44%	-2.52%	-28.47%	-88.62%
PRLD Prelude Therapeutics	-0.62%	-3.26%	-15.12%	+5.83%	-85.63%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
KRON Kronos Bio	2.4278 of 5 stars	3.2	0.0	0.0	4.2	1.3
PEPG PepGen	3.0862 of 5 stars	3.2	4.0	1.7	2.5	1.3
PHGE BiomX	2.2212 of 5 stars	3.5	0.0	1.7	0.8	1.3
PRLD Prelude Therapeutics	3.6783 of 5 stars	3.5	5.0	2.7	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KRON Kronos Bio	2.33	Hold	$1.63	84.66% Upside
PEPG PepGen	2.33	Hold	$7.67	518.28% Upside
PHGE BiomX	3.00	Buy	$21.00	5,326.36% Upside
PRLD Prelude Therapeutics	3.00	Buy	$4.50	452.21% Upside

Current Analyst Ratings Breakdown

Latest PHGE, KRON, PRLD, and PEPG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/29/2025	PEPG PepGen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $8.00
5/16/2025	PHGE BiomX	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/9/2025	PEPG PepGen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $14.00
5/5/2025	PRLD Prelude Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/29/2025	PRLD Prelude Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$4.00 ➝ $4.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KRON Kronos Bio	$9.85M	5.45	N/A	N/A	$1.45 per share	0.61
PEPG PepGen	N/A	N/A	N/A	N/A	$3.64 per share	N/A
PHGE BiomX	N/A	N/A	N/A	N/A	$0.70 per share	N/A
PRLD Prelude Therapeutics	$7M	6.57	N/A	N/A	$2.39 per share	0.34

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KRON Kronos Bio	-$86.08M	-$1.07	N/A	N/A	N/A	-701.53%	-64.22%	-47.17%	8/6/2025 (Estimated)
PEPG PepGen	-$89.98M	-$3.13	N/A	N/A	N/A	N/A	-81.26%	-63.65%	8/14/2025 (Estimated)
PHGE BiomX	-$28.32M	-$0.85	N/A	N/A	N/A	N/A	-127.82%	-56.50%	N/A
PRLD Prelude Therapeutics	-$127.17M	-$1.69	N/A	N/A	N/A	N/A	-89.18%	-69.26%	8/11/2025 (Estimated)

Latest PHGE, KRON, PRLD, and PEPG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	PRLD Prelude Therapeutics	-$0.45	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	PEPG PepGen	-$0.8150	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	PEPG PepGen	-$0.72	-$0.92	-$0.20	-$0.92	N/A	N/A
5/6/2025	Q1 2025	PRLD Prelude Therapeutics	-$0.47	-$0.42	+$0.05	-$0.42	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
KRON Kronos Bio	N/A	N/A	N/A	N/A	N/A
PEPG PepGen	N/A	N/A	N/A	N/A	N/A
PHGE BiomX	N/A	N/A	N/A	N/A	N/A
PRLD Prelude Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KRON Kronos Bio	N/A	12.93	12.93
PEPG PepGen	N/A	4.95	4.95
PHGE BiomX	0.51	2.84	2.84
PRLD Prelude Therapeutics	N/A	5.18	5.18

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KRON Kronos Bio	64.09%
PEPG PepGen	58.01%
PHGE BiomX	40.57%
PRLD Prelude Therapeutics	79.72%

Insider Ownership

Company	Insider Ownership
KRON Kronos Bio	24.40%
PEPG PepGen	4.60%
PHGE BiomX	1.17%
PRLD Prelude Therapeutics	63.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KRON Kronos Bio	100	61.05 million	46.16 million	Optionable
PEPG PepGen	30	32.72 million	31.22 million	Not Optionable
PHGE BiomX	120	26.18 million	44.04 million	Not Optionable
PRLD Prelude Therapeutics	120	56.46 million	20.38 million	Optionable

PHGE, KRON, PRLD, and PEPG Headlines

Recent News About These Companies

Prelude Therapeutics Incorporated (PRLD) - Yahoo Finance

June 25, 2025 | finance.yahoo.com

Prelude Therapeutics Incorporated (PRLD) - Yahoo Finance

June 25, 2025 | finance.yahoo.com

Prelude Therapeutics to Present at Major Healthcare Conferences in June 2025

June 3, 2025 | msn.com

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

June 2, 2025 | globenewswire.com

Prelude Therapeutics’ SWOT analysis: clinical progress buoys stock amid challenges

May 28, 2025 | investing.com

Pathos AI secures $365M series D to fund trial of Novo Nordisk solid tumor drug

May 15, 2025 | fiercebiotech.comF

Prelude Therapeutics Reports Q1 2025 Financial Results and Progress on Clinical Programs

May 10, 2025 | msn.com

Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 6, 2025 | globenewswire.com

Prelude Therapeutics to Host Fireside Chat at Citizens Life Sciences Conference 2025

May 4, 2025 | msn.com

Prelude Therapeutics to Participate in Citizens Life Sciences Conference

May 1, 2025 | globenewswire.com

Prelude Therapeutics Unveils Promising Preclinical Data on Novel Cancer Therapies

April 30, 2025 | msn.com

Prelude Announces Presentations at 2025 AACR Annual Meeting

April 25, 2025 | globenewswire.com

Prelude Therapeutics (PRLD) Upgraded to Buy: Here's What You Should Know

April 10, 2025 | zacks.com

Prelude Therapeutics Founder Acquires 28% More Stock

March 29, 2025 | finance.yahoo.com

Prelude Therapeutics CEO buys $467K in common stock

March 28, 2025 | markets.businessinsider.com

Prelude Therapeutics Incorporated (NASDAQ:PRLD) Insider Buys $69,000.00 in Stock

March 28, 2025 | insidertrades.com

Prelude Therapeutics stock surges on insider buying

March 27, 2025 | investing.com

Prelude Therapeutics Incorporated (NASDAQ:PRLD) CEO Krishna Vaddi Purchases 47,500 Shares

March 15, 2025 | insidertrades.com

Prelude Therapeutics Reports 2024 Financial Results and Clinical Pipeline Advancements

March 14, 2025 | msn.com

Analysts Are Bullish on Top Healthcare Stocks: Prelude Therapeutics (PRLD), Corbus Pharmaceuticals (CRBP)

March 12, 2025 | markets.businessinsider.com

Media Sentiment Over Time

PHGE, KRON, PRLD, and PEPG Company Descriptions

Kronos Bio NASDAQ:KRON

$0.88 +0.01 (+1.49%)

As of 06/20/2025

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.

PepGen NASDAQ:PEPG

$1.24 -0.05 (-3.88%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$1.25 +0.01 (+0.48%)

As of 07:32 AM Eastern

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.

BiomX NYSEMKT:PHGE

$0.39 -0.35 (-47.63%)

Closing price 07/15/2025 03:59 PM Eastern

Extended Trading

$0.39 +0.00 (+0.26%)

As of 07:46 AM Eastern

BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company's product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

Prelude Therapeutics NASDAQ:PRLD

$0.81 0.00 (-0.50%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$0.86 +0.04 (+5.04%)

As of 07/15/2025 04:27 PM Eastern

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time